BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Retina
,
Nosology
,
Prozac
,
rs7903146
,
PRKCA
,
Coagulation
,
Influenza
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
MLN8237
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
PRPH
MYBL2
MAL
H19
Fndc3c1
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
FISCHER_DREAM_TARGETS
GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN
organic cyclic compound metabolic process
heterocycle metabolic process
cellular aromatic compound metabolic process
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Neuroblastoma mNB-A1 cell line treated with BRD4 or AURKA inhibitors
Lung cancer KRAS-mutant A549 cells treated with aurora kinase inhibitors VX680, AZD1152, and MLN8237
Pancreatic ductal cancer PANC-1 cells treated with chaetocin or MLN 8237 alone or in combination
Explore Curated Studies Results
Literature
Most Relevant Literature
Differentiation therapy for murine myelofibrosis model with MLN8237 loaded low-density lipoproteins.
Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth.
Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors.
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma.
Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigatio…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Study of MLN8237 in Combination With Irinotecan and Temozolomide
MLN8237 for a Subject With Adenocarcinoma of the Prostate
MLN8237 in Head and Neck Cancer
MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prosta…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ